Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06154837 · ClinicalTrials.gov registry record · Phase 1
A Study for GSK3862995B in Healthy Participants and Participants With Chronic Obstructive Pulmonary Disease
A Phase 1 study of Pulmonary Disease, Chronic Obstructive, sponsored by GlaxoSmithKline.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 130
- Enrollment target
- 20
- Study locations
NCT06154837: Recruiting Phase 1 study of Pulmonary Disease, Chronic Obstructive, sponsored by GlaxoSmithKline.
NCT06154837 is a Phase 1 study of Pulmonary Disease, Chronic Obstructive that is actively recruiting participants, run by GlaxoSmithKline. The registered enrollment target is 130 participants, below the 1,042-participant average among 74 other Pulmonary Disease, Chronic Obstructive trials with a reported enrollment target (88% lower). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06154837, a Phase 1 study of Pulmonary Disease, Chronic Obstructive, is actively recruiting participants, sponsored by GlaxoSmithKline.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 130 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objective of the study is to investigate the safety and tolerability of ascending doses of GSK3862995B following single dose in healthy participants and repeat doses in participants with Chronic obstructive pulmonary disease (COPD).
Primary Outcome
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. Any untoward event resulting in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in persisting disability/incapacity, congenital anomaly/birth defect or any other situation according to medical or scientific judgment is categorized as SAE.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG GSK3862995B
Study Locations (20)
Other
- GSK Investigational Site - Ahrensburg
- GSK Investigational Site - Berlin
- GSK Investigational Site - Berlin
- GSK Investigational Site - Berlin
- GSK Investigational Site - Dresden
- GSK Investigational Site - Frankfurt
- GSK Investigational Site - Hamburg
- GSK Investigational Site - Hamburg
- GSK Investigational Site - Hanover
- GSK Investigational Site - Immenhausen
- GSK Investigational Site - Leipzig
Florida
- GSK Investigational Site - Hialeah
- GSK Investigational Site - Plantation
North Carolina
- GSK Investigational Site - Shelby
- GSK Investigational Site - Wilmington
Arizona
- GSK Investigational Site - Yuma
Georgia
- GSK Investigational Site - Columbus
Oregon
- GSK Investigational Site - Medford
South Carolina
- GSK Investigational Site - Rock Hill
Texas
- GSK Investigational Site - Austin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 130 participants |
| Start Date | 2023-11-27 |
| Est. Completion | 2027-03-31 |
| Phase | Phase 1 |
What NCT06154837 shows while recruiting
NCT06154837 is an interventional study that assigns participants to a tested intervention. The registered 130 participants enrollment target is mid-sized for trials with a published cap, below the 1,042-participant average among 74 other Pulmonary Disease, Chronic Obstructive trials with a reported enrollment target (88% lower).
The record links to 1 condition, with Pulmonary Disease, Chronic Obstructive appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06154837 names 20 study sites across 8 states, led by Other, Florida, North Carolina.
Frequently Asked Questions
What is clinical trial NCT06154837 about?
NCT06154837 is a clinical study titled "A Study for GSK3862995B in Healthy Participants and Participants With Chronic Obstructive Pulmonary Disease". The primary objective of the study is to investigate the safety and tolerability of ascending doses of GSK3862995B following single dose in healthy participants and repeat doses in participants with Chronic obstructive pulmonary disease (COPD).
What is the current status of trial NCT06154837?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 130 participants. The study started on 2023-11-27. Estimated completion is 2027-03-31.
What conditions does trial NCT06154837 study?
This clinical trial studies the following conditions: Pulmonary Disease, Chronic Obstructive.
What interventions are being tested in trial NCT06154837?
The interventions under investigation include: Placebo (DRUG), GSK3862995B (DRUG).
Who is sponsoring clinical trial NCT06154837?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06154837 being conducted?
This trial has 20 study locations across Arizona, Florida, Georgia, North Carolina, Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pulmonary Disease, Chronic Obstructive
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06154837's enrollment target sits among peer trials
130 51st of 74 higher than 24 of 74 other Pulmonary Disease, Chronic Obstructive trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pulmonary Disease, Chronic Obstructive trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics (PK) of Nemiralisib
COMPLETED · Phase 1
-
Transforming Psychotherapy for Chronically Ill Patients
COMPLETED · Phase 1
-
Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GSK2269557 Administered Via the ELLIPTA Dry Powder Inhaler to Healthy Subjects
COMPLETED · Phase 1
-
Real-Time Support for Exercise Persistence in COPD
COMPLETED · Phase 1
-
A Study to Investigate the Safety and Pharmacokinetics of a Single Dose of GSK2256294 in Healthy Young Males and Elderly Subjects
COMPLETED · Phase 1
-
Pharmacokinetic Study in Healthy Volunteers to Characterise the Exposure of Fluticasone Furoate (FF), Vilanterol (VI) and Umeclidinium (UMEC) at Two Different Doses
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01492036 · 130 participants
Long-Term Follow-Up of Recipient of Gene Transfer Research
- NCT01631617 · 130 participants · Phase 2
Effects of Treatments on Atopic Dermatitis
- NCT02368041 · 130 participants
Utility of Thenar Near Infrared Spectroscopy (NIRS) in Pediatric Patients With Heart Failure
- NCT02604277 · 130 participants · NA
Suicidal Behavior in Patients Diagnosed With Bipolar Disorder
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI